Business Context and Reporting Period
Company: Atea Pharmaceuticals, Inc. (AVIR)
Filing Type: Form 8-K (Current Report)
Report Date: February 28, 2022
Context: The filing announces the issuance of a press release containing financial results for the three months and full year ended December 31, 2021. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not embedded in the body of this 8-K text.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being disclosed in the press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
No specific material changes or comparative financial data versus prior periods are detailed in this document. The filing serves solely as a notification that results for the period ended December 31, 2021, have been released.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release dated February 28, 2022, which contains other matters described by management.
Legal Status: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other documents unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2021.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the company's common stock trading on The Nasdaq Global Select Market.